Please login to the form below
colorectal cancer
This page shows the latest colorectal cancer news and features for those working in and with pharma, biotech and healthcare.
Nektar confirms BMS deal for NKTR-214 is on track
Robin said that studies are now underway or planned for the CD122-biased agonist in small cell lung cancer (SCLC), breast cancer, colorectal cancer, gastric cancer, triple-negative breast cancer (TNBC) ... Combination trials in head and neck cancer and
Latest news
-
Sanofi and Regeneron re-jig immuno-oncology deal
That candidate is currently in trials for ovarian cancer, but it has potential in cancers expressing the MUC16 biomarker is also frequently expressed in lung, pancreatic, gastric and colorectal cancer.
-
Horizon Discovery and C4X to harness CRISPR for new cancer drugs
These work by targeting a specific DNA repair pathway that cancer cells, with mutations such as BRCA, become over-reliant on. ... The companies say they will be focused on discovering new compounds in therapy areas with treatments of limited effectiveness
-
Chi-Med and Lilly’s cancer drug Elunate a milestone for China
cancer in China every year, making it the country's second most common cancer type behind lung cancer. ... Elunate is approved for treatment of patients with metastatic colorectal cancer (CRC) previously treated with fluoropyrimidine, oxaliplatin and
-
MS and cholesterol drugs picked for new UK rapid uptake push
Quantitative faecal immunochemical tests for colorectal cancer - Diagnostic tests that reduce referrals for patients with suspected colorectal cancer.
-
Home-grown colorectal cancer drug approved in China
China for colorectal cancer (CRC). ... China looks set to be a big market for the drug in its own right, however, as CRC is the second-most common form of cancer with an estimated 380, 000
More from news
Approximately 15 fully matching, plus 199 partially matching documents found.
Latest Intelligence
-
Pharma deals continue to slide
CAP7.1 prodrug of etoposide at start phase 3 for second line treatment of biliary tract cancer. ... Phase III toll-like receptor 9 agonist for metastatic colorectal cancer. 124.
-
Winning the war against cancer
data sources and the organisation of screening programmes for colorectal cancer. ... Cancer is an important disease to see [its] impact on the health system.
-
Deal Watch September 2016
Dr Reddy's has expanded its collaboration with Amgen in India adding three approved products: Xgeva for treating bone metastases, Vectibix in colorectal cancer therapy and Prolia for osteoporosis. ... Janssen granted Tracon Pharmaceuticals the rights to
-
Pharma deals during February 2014
awarded FDA breakthrough therapy status for advanced melanoma last year, and is being studied in 13 clinical trials across more than 30 types of cancer. Financial terms for these deals were ... BATON studies in colorectal cancer and metastatic triple
-
The oncology market in Canada
on the other side of the border, three tumours have comparable incidence rates, while colorectal cancer is a distant number four. ... Colorectal cancer. Colorectal cancer is where the two countries demonstrate the most substantial differences.
More from intelligence
Approximately 1 fully matching, plus 9 partially matching documents found.
Latest appointments
-
BMS appoints oncology development head
On moving to the US in 2006, Dr Namouni took over responsibility for metastatic colorectal cancer treatment Erbitux (cetuximab), before serving as development lead for Opdivo (nivolumab) and Yervoy (ipilimumab).
-
Kite Pharma appoints head of regulatory affairs
colorectal cancer. ... Other recent additions include chief financial officeras chief medical officer; and several cancer experts to the company's scientific advisory board.
-
Boston Biomedical appoints commercial head
colorectal cancer.
-
Mirna hires former Pfizer director as CMO
Prior to this, he was director of clinical oncology at Bristol-Myers Squibb where he worked on the clinical development of Erbitux (cetuximab), which is approved for colorectal cancer and head ... This background will benefit Mirna, which has just
More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
Proctologic Table Market Volume Analysis, Segments, Value Share and Key Trends
The proctologic table is an innovative medical research for treating the patients suffering from anal fissures, colon polyps, colorectal cancer, Crohn’s disease, constipation, gallstones, diverticulitis, haemorrhoids, hernias, irritable bowel
-
Artificial Intelligence in Healthcare
trust the same digital system to recommend their treatment pathway for a potentially lethal cancer. ... Early experience with IBM Watson for Oncology (WFO) cognitive computing system for lung and colorectal cancer treatment.
-
Lynch syndrome: a patient perspective
My grandfather was probably the first in the family to be afflicted with Lynch syndrome or Hereditary Nonpolyposis Colorectal Cancer (HNPCC). ... colon cancer as a cause of death in families where half their members previously died for the disease.
-
90TEN nominated for five Communiqué Awards
Meanwhile two of the agency’s campaigns for Sirtex - in collaboration with Denovo Strategy - in metastatic colorectal liver cancer are shortlisted, for Excellence in Media Relations and Excellence in Integrated
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
Featured jobs
-
Digital Account Director
-
Salary TBC
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
-
Senior Medical Writer
-
Salary TBC
-
Account Director, Medical Education
-
Salary TBC
-
Project Manager/ Account Manager
-
Salary TBC
-
Senior Medical Writer
-
Great salary and benefits
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
-
Senior Medical Writer
-
Up to £50, 000 with Benefits
Subscribe to our email news alerts
- Drug launches to watch in 2019
- Welcome to the Communique Awards - Communiqué Awards 2018
- ‘Inflexible’ NICE blocking access to rare disease drugs
- 2019: CRISPR and therapeutic gene editing comes of age
- GW Pharma's cannabis-based medicine to be tested in dementia
- More good news, and some bad, for Merck’s Keytruda
- BioMarin prepares for haemophilia A gene therapy data readout, filing
- Innovent gears up for PD-1 inhibitor launch in China
- NICE knocks back BioMarin’s Batten disease drug
- Amgen, Servier start second phase 3 trial of heart failure hope
- The importance of co-creation with patients
- McCann Health's next challenge: creative differentiation
PMHub
Bedrock Healthcare Communications
Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...
Latest intelligence
- The importance of co-creation with patients
- Overcoming the barriers...
- Three billboards on the road to multichannel
- Chris Ross examines the trends driving multichannel communication in 2019...
- How Medisafe is using AI to improve patient adherence
- Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....
Quick links
Infographics
